FOx Biosystems
Open bankruptcySummary
A bankruptcy procedure is open for FOx Biosystems according to publications in the Belgian State Gazette. The 2023 annual accounts show equity of €1.3m and a net result of -€2.8m.
Are you a creditor?
Open bankruptcy
Source: Belgian Official Gazette
If this company owes you money, you are not paid automatically: you file your claim yourself, within the deadline the judgment sets.
The procedure
- Court
- Enterprise Court of Antwerp, Hasselt division
- Declared bankrupt
- 23 January 2025
- Supervising judge
- Ivo Van Genechten
- Official Gazette
- 29-01-2025 (pdf) ↗search the document for 2025/103697
Deadlines
- Provisional date payments stopped
- 15 January 2025Payments and security you received since that day can in some cases be challenged by the curator. A later judgment can change the date.art. XX.105, XX.111 and XX.112 CEL
- Appeal or third-party opposition until
- passed on 13 February 2025Fifteen days after the publication in the Official Gazette.art. XX.108 CEL
- File the claim in RegSol until
- passed on 22 February 2025art. XX.104 and XX.155 CEL
- First verification report
- passed on 6 March 2025Goods that belong to you, such as those delivered under retention of title, are reclaimed before this day.art. XX.104 and XX.194 CEL
- Late claim until
- passed on 23 January 2026Late, you share only in what has not been paid out yet, and the costs are yours.art. XX.165 CEL
Curators
- Geert ReniersJaarbeurslaan 19/31, 3600 Genkgeert.reniers@paqt.be
- Tom ArtsJaarbeurslaan 19/31, 3600 Genktom.arts@paqt.be
- Ilona Lo GiudiceJaarbeurs- Laan 19/31, 3600 Genkilona.logiudice@paqt.be
What to do now
- Do not deliver on credit any more without an agreement with the curator.
- Gather your documents: invoices, purchase orders, contract, delivery notes and reminders.
- File your proof of claim in RegSol (regsol.be), yourself with eID or itsme, or through your lawyer. State principal, interest and costs separately, and any preferential right you hold.
- Delivered under retention of title? Reclaim your goods before the first report on the verification of claims.
- Ask your accountant about the VAT on the unpaid invoices: in a bankruptcy it can be recovered under conditions.
- Follow the file in RegSol: the verification report (admitted or disputed) and the curator's reports appear there.
The deadlines above come from the publication of the judgment. Check them in RegSol before you file anything; a passed deadline no longer applies.
File a claim in RegSol ↗
Watch
Follow this bankruptcy: you are alerted when it is closed or reversed.
General information, not legal advice. If in doubt, the curator, your lawyer or your accountant can help.Creditor guide for this company
Embed in an article
Writing about this bankruptcy? Put the card of FOx Biosystems in your article: name, enterprise number, its status in the KBO and the latest annual accounts, with a link to this dossier.
Preview
The preview appears here.
- Stays current: the status follows the register, the figures are those of the latest filed accounts. No Checked score or verdict.
- Light on your page: one small script and one data request, also answered from a cache; no cookies, no tracking.
- Where scripts do not run (a newsletter, a feed reader) a plain link remains.
Signals
Three signals. The signal on the left, the evidence on the right.
+raises risk○neutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2023 was due by 31-07-2024 and was filed on 09-07-2024, 22 days ahead of the deadline.
NBB · 8 filingsDeviation from the deadline
2025
not confirmed
2024
not filed
2023
22 d early
2022
27 d early
2021
23 d early
2020
23 d early
2019
16 d early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 5 accounts on average 22 days before the deadline; the sector median for financial year 2024 is 13 days before the deadline, and 32% of the sector filed late.
Checked, nothing found (1)
History
Go further with this company
Who ran this company, and where was it based, on a date before the end?Company as of a date Are there other customers at risk in your own list?List enrichment How is the Research and development on biotechnology sector doing?Sector figures
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2023, abbreviated schema
Equity
€1.3m▼ 47.9%
2022 · €2.5m
Total assets
€2.7m▼ 9.5%
2022 · €3.0m
Net result
-€2.8m▲ 16.4%
2022 · -€3.3m
Working capital
€602,681▼ 57.4%
2022 · €1.4m
Trend over the years
Click a name to add, emphasise or remove a line.Band: the middle half (P25 to P75) of NACE 72, Scientific research and development, each year against the same schema; no band under 30 filings. Dashed line: the median.
Every figure with its change against the fiscal year before
favourable
unfavourable
Line20192020202120222023
Operating result-€585,336▼ 491%-€1.2m▼ 107%-€2.4m▼ 97.8%-€3.3m▼ 36.3%-€2.9m▲ 11.1%
Net result-€452,764▼ 357%-€1.1mbelow the sector's middle half▼ 152%-€2.3mbelow the sector's middle half▼ 100%-€3.3mbelow the sector's middle half▼ 46.1%-€2.8mbelow the sector's middle half▲ 16.4%
Equity€3.0m€3.7mabove the sector's middle half▲ 22.3%€1.3mwithin the sector's middle half▼ 63.9%€2.5mwithin the sector's middle half▲ 87.2%€1.3mwithin the sector's middle half▼ 47.9%
Total assets€3.2m▲ 2,025%€3.9mabove the sector's middle half▲ 23.7%€4.4mwithin the sector's middle half▲ 13.8%€3.0mwithin the sector's middle half▼ 32.4%€2.7mwithin the sector's middle half▼ 9.5%
Debt€167,522▲ 11.6%€246,382▲ 47.1%€3.1m▲ 1,168%€530,890▼ 83.0%€1.4m▲ 169%
Working capital€1.6m€1.9m▲ 22.9%€2.4m▲ 25.7%€1.4m▼ 42.0%€602,681▼ 57.4%
Solvency94.7%▲ 95.7pp93.7%above the sector's middle half▼ 1.0pp29.7%within the sector's middle half▼ 64.0pp82.3%above the sector's middle half▲ 52.6pp47.5%within the sector's middle half▼ 34.9pp
Staff (FTE)1.76.7above the sector's middle half▲ 294%9within the sector's middle half▲ 34.3%12.1within the sector's middle half▲ 34.4%13.8within the sector's middle half▲ 14.0%
above
within
below
the middle half (P25 to P75) of NACE 72, Scientific research and development, each year against the same schema; no band under 30 filings.
Turnover and EBIT margin not published: the abbreviated or micro schema does not require them.
Why a figure moved sharply
- 2021 Net result -100% on 2020. The accounts now follow the abbreviated schema, last year the micro schema.
Result per fiscal year
Operating resultNet result
The operating result stays negative: a loss of €2.9m in 2023 against €3.3m in 2022; the loss shrinks.
Balance-sheet composition
2023 in colour, 2022 as the grey bar beneath
Assets €2.7m
Fixed assets
€1.5m ▲ 25.7%
Current assets
€1.2m ▼ 33.0%
Equity and liabilities €2.7m
Equity
€1.3m ▼ 47.9%
Debt
€1.4m ▲ 169%
Debt's share of the balance-sheet total rises from 17.7% to 52.5%. Equity is lower and debt is higher.
Key figures and ratios
EBITDA
-€2.3m▲
2022 · -€2.6m
Cash flow
-€2.2m▲
2022 · -€2.7m
Current ratio
1.99▼
2022 · 4.65
Quick ratio
1.59▼
2022 · 4.18
Debt to equity
1.11▲
2022 · 0.21
ROE
-216.0%▼
2022 · -134.8%
ROA
-102.5%▲
2022 · -111.0%
Interest coverage
-96.01▼
2022 · -17.06
Debt ≤ 1 year
€606,033▲
2022 · €388,294
Debt > 1 year
€33,024▲
2022 · €0
Income taxes
-€30,887▼
2022 · €17,745
Staff costs
€1.4m▲
2022 · €1.1m
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Annual accounts
| Line | 2019 | 2020 | 2021 | 2022 | 2023 | Change |
|---|---|---|---|---|---|---|
| Remuneration, social security and pensions62 | - | - | €739,127 | €1.1m | €1.4m | ▲ 22.5% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €162,610 | €389,225 | €602,943 | €652,277 | €603,282 | ▼ 7.5% |
| Other operating charges640/8 | - | - | €7,629 | €2,069 | €126,776 | ▲ 6,027% |
| Gross operating margin9900 | -€303,434 | -€298,906 | -€1.0m | -€1.5m | -€763,895 | ▲ 47.7% |
| Operating profit (loss)9901 | -€585,336 | -€1.2m | -€2.4m | -€3.3m | -€2.9m | ▲ 11.1% |
| Financial income75/76B | - | - | €117,577 | €96,133 | €105,874 | ▲ 10.1% |
| Recurring financial income75 | €133,025 | €72,251 | €117,577 | €96,133 | €105,874 | ▲ 10.1% |
| Financial charges65/66B | - | - | €6,859 | €153,055 | €23,936 | ▼ 84.4% |
| Recurring financial charges65 | €312 | €2,322 | €6,859 | €153,055 | €23,936 | ▼ 84.4% |
| Profit (loss) for the period before taxes9903 | -€452,623 | -€1.1m | -€2.3m | -€3.3m | -€2.8m | ▲ 15.1% |
| Income taxes67/77 | €141 | €687 | €1,053 | €17,745 | -€30,887 | ▼ 274% |
| Profit (loss) for the period9904 | -€452,764 | -€1.1m | -€2.3m | -€3.3m | -€2.8m | ▲ 16.4% |
| Profit (loss) for the period to be appropriated9905 | -€452,764 | -€1.1m | -€2.3m | -€3.3m | -€2.8m | ▲ 16.4% |
| Line | 2019 | 2020 | 2021 | 2022 | 2023 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €3.2m | €3.9m | €4.4m | €3.0m | €2.7m | ▼ 9.5% |
| Fixed assets21/28 | €1.4m | €1.7m | €1.7m | €1.2m | €1.5m | ▲ 25.7% |
| Intangible fixed assets21 | €1.3m | €1.5m | €1.5m | €1.0m | €1.2m | ▲ 20.9% |
| Tangible fixed assets22/27 | €101,712 | €218,846 | €222,592 | €157,838 | €243,614 | ▲ 54.3% |
| Plant, machinery and equipment23 | - | - | €216,094 | €150,796 | €100,403 | ▼ 33.4% |
| Furniture and vehicles24 | - | - | €6,498 | €7,041 | €41,630 | ▲ 491% |
| Other tangible fixed assets26 | - | - | - | - | €101,582 | - |
| Financial fixed assets28 | €7,860 | €11,223 | €17,558 | €18,619 | €27,070 | ▲ 45.4% |
| Current assets29/58 | €1.7m | €2.2m | €2.7m | €1.8m | €1.2m | ▼ 33.0% |
| Stocks and contracts in progress3 | €47,167 | €14,962 | €170,324 | €182,672 | €244,034 | ▲ 33.6% |
| Stocks30/36 | - | - | €170,324 | €182,672 | €244,034 | ▲ 33.6% |
| Amounts receivable within one year40/41 | €494,431 | €394,482 | €129,955 | €215,439 | €299,109 | ▲ 38.8% |
| Trade receivables40 | - | - | €73,246 | €127,157 | €176,635 | ▲ 38.9% |
| Other amounts receivable41 | - | - | €56,709 | €88,282 | €122,473 | ▲ 38.7% |
| Cash at bank and in hand54/58 | €1.2m | €1.8m | €2.4m | €1.4m | €620,854 | ▼ 54.6% |
| Deferred charges and accrued income490/1 | - | - | €35,016 | €39,221 | €44,718 | ▲ 14.0% |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €3.2m | €3.9m | €4.4m | €3.0m | €2.7m | ▼ 9.5% |
| Equity10/15 | €3.0m | €3.7m | €1.3m | €2.5m | €1.3m | ▼ 47.9% |
| Contributions10/11 | €496,704 | €662,655 | €5.2m | €9.8m | €4.5m | ▼ 53.9% |
| Capital10 | - | - | €662,655 | €5.2m | €1.2m | ▼ 77.2% |
| Issued capital100 | - | - | €662,655 | €6.4m | €1.2m | ▼ 81.5% |
| Uncalled capital101 | - | - | - | €1.2m | €0 | ▼ 100% |
| Outside capital11 | - | - | €4.6m | €4.6m | €3.3m | ▼ 27.2% |
| Share premium1100/10 | - | - | €4.6m | €4.6m | €3.3m | ▼ 27.2% |
| Profit (loss) carried forward14 | -€647,813 | -€1.8m | -€4.1m | -€7.4m | -€3.7m | ▲ 50.1% |
| Investment grants15 | - | - | €152,747 | €56,638 | €460,764 | ▲ 714% |
| Amounts payable17/49 | €167,522 | €246,382 | €3.1m | €530,890 | €1.4m | ▲ 169% |
| Amounts payable after more than one year17 | - | - | €2.7m | €0 | €33,024 | - |
| Financial debts170/4 | - | - | €2.7m | €0 | - | - |
| Trade debts175 | - | - | - | - | €33,024 | - |
| Amounts payable within one year42/48 | €167,522 | €242,729 | €300,852 | €388,294 | €606,033 | ▲ 56.1% |
| Financial debts43 | - | - | €2,776 | €0 | - | - |
| Credit institutions430/8 | - | - | €2,776 | €0 | - | - |
| Trade debts44 | €132,267 | €125,888 | €157,139 | €322,105 | €444,948 | ▲ 38.1% |
| Suppliers440/4 | - | - | €157,139 | €322,105 | €444,948 | ▲ 38.1% |
| Taxes, remuneration and social security45 | - | - | €140,936 | €66,016 | €161,085 | ▲ 144% |
| Taxes450/3 | - | - | €11,468 | €2,634 | €73,058 | ▲ 2,674% |
| Remuneration and social security454/9 | - | - | €129,468 | €63,382 | €88,027 | ▲ 38.9% |
| Other amounts payable47/48 | - | - | - | €173 | €0 | ▼ 100% |
| Accrued charges and deferred income492/3 | - | - | €174,420 | €142,596 | €789,927 | ▲ 454% |
| Line | 2019 | 2020 | 2021 | 2022 | 2023 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | -€452,764 | -€1.1m | -€2.3m | -€3.3m | -€2.8m | ▲ 16.4% |
| + Depreciation and write-downs630 | €162,610 | €389,225 | €602,943 | €652,277 | €603,282 | ▼ 7.5% |
| Operating cash flow (approximation) | -€290,154 | -€751,983 | -€1.7m | -€2.7m | -€2.2m | ▲ 18.6% |
| Investment in fixed assets (approximation) | - | -€699,592 | -€585,280 | -€147,458 | -€912,386 | ▼ 519% |
| Change in cash | - | €556,492 | €645,437 | -€1.0m | -€746,087 | ▲ 28.2% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
2025
29-01
Bankruptcy
Opening
Ondernemingsrechtbank Antwerpen, afdeling Hasselt · event 23-01-2025
2024
09-07
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema
2023
04-07
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema
2022
31-12
Financial
Weakest financial yearnet -€3.3m
Net result drops to -€3.3m, the lowest in the series.
31-12
Financial
Equity above €2mEq €2.5m ▲87.2%
Equity rises from €1.3m to €2.5m.
08-07
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema
2021
08-07
NBB filing
Annual accounts filed
fiscal year 2020 · micro schema
2020
15-07
NBB filing
Annual accounts filed
fiscal year 2019 · micro schema
2019
31-12
Financial
Liquidity times 19current ratio 10.42
Current ratio from 0.54 to 10.42.
31-12
Financial
Equity above €2mEq €3.0m
Equity rises from -€1,439 to €3.0m.
10-07
NBB filing
Annual accounts filed
fiscal year 2018 · micro schema
2018
16-07
NBB filing
Annual accounts filed
fiscal year 2017 · micro schema
2017
12-06
NBB filing
Annual accounts filed
fiscal year 2016 · micro schema
SignalFinancial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 17 acts read
About the unread acts
We know of 17 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
17 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Diepenbeek · 2 establishment units since 2016
Ground area
3.2 ha
Building footprint
1,934 m²
Volume, LiDAR
28,704 m³
2 parcels, Flanders · tallest building 20.0 m, ±5 floors. Linked by address, not a title deed.
2 establishment units
FOx Biosystems
since 20162.254.601.484
FOx Biosystems
since 20232.342.173.282
2 parcels
Flanders
2
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 71011A0272/00F000 | Flanders | 2.5 ha | - | - |
| 44082B0103/00E000 | Flanders | 6,306 m² | 1 · 1,934 m² | 20.0 m · 5 fl. |
Linked by address, not proof of ownership
Good to know
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Insolvency mandates
3 mandates| Role | Name | Tenure |
|---|---|---|
| Curator | GEERT RENIERS JAARBEURSLAAN 19/31, 3600 GENK- |
23-01-2025 → present |
| Curator | TOM ARTS JAARBEURSLAAN 19/31,
3600 GENK |
23-01-2025 → present |
| Curator | ILONA LO GIUDICE JAARBEURS-
LAAN 19/31, 3600 GENK |
23-01-2025 → present |
Structure & network
Owners and holdings
2 owners · 1 holdingOwners 2
-
33.94%
-
28.16%
Holdings 1
-
100%
According to the 2023 annual accounts of FOx Biosystems and those of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.
Connections & network
No current directors or connected companies found in the register.
Public money · subsidies and aid
Flemish government
2023 to 2025 · 4 entries · 268,333 EUR awarded · 268,333 EUR paid| Year | Entries | awarded | paid |
|---|---|---|---|
| 2025 | 1 | -234,000 EUR | 0 EUR |
| 2024 | 2 | 2,333 EUR | 135,333 EUR |
| 2023 | 1 | 500,000 EUR | 133,000 EUR |
European Union, budget
2023 · 2 entries · 2,499,999 EUR in total| Year | Entries | awarded |
|---|---|---|
| 2023 | 2 | 2,499,999 EUR |
Projects
EV FOX - EXTRACELLULAR VESICLES FIBER OPTIC SURFACE PLASMON RESONANCE SELECTION AND ANALYSIS
European research
5 projects · 1 as coordinator · 2,726,201 EUR EU contributionProgrammes
Projects
Extracellular Vesicles Fiber Optic Surface Plasmon Resonance selection and analysis
A game change in continuous biosensing: Molecularly engineered affinity-based nanoswitches for personal monitoring
Selective Plasmonic Sensors based on Quantum Electron Transfer
Protease‐guided tumor targeting tools to revolutionize cancer diagnosis and treatment.
Extracellular Vesicle Research Exchanges for Advanced Biomarkers and Therapeutics
Similar companies · same sector, comparable size
Docteur Benoît GLORIEUX
BE 0884.319.405
Tournai · Eq €1,327,178
Fishway
BE 0787.869.632
Leuven · Eq €1,332,626
Flanders’ FOOD
BE 0878.017.175
Sint-Joost-ten-Node · Eq €1,346,419
ConvEyXo
BE 0725.874.259
Charleroi · Eq €1,388,840
ImmunXperts
BE 0552.755.587
Charleroi · Eq €1,403,965
Of 762 companies in sector 72101 we hold annual accounts for 483. 289 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPublic limited company
Founded03-05-2016
Fiscal year end31-12
Activities, NACEBEL 2025
72101Research and development on biotechnology
73300Public relations and communication consultancy
74999Other professional, scientific and technical activities
Contact
Website
www.foxbiosystems.com
E-mail
info@foxbiosystems.com
Phone
+32 11 286 973
E-mail
filipdelport@hotmail.comDiepenbeek
Phone
0498489042Diepenbeek
E-invoicing
Not found in the Peppol register
No Peppol card under this enterprise or VAT number. That proves nothing: publishing a card is voluntary.
Register as of 27 September 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.